Literature DB >> 7795416

alpha 1-Acid glycoprotein binds human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein via N-linked glycans.

L Rabehi1, F Ferriere, L Saffar, L Gattegno.   

Abstract

In the present study, we demonstrate a specific low-affinity interaction between recombinant precursor gp160 (rgp160) or surface unit gp120 (rgp120) of human immunodeficiency virus type 1 (HIV-1) and alpha 1-acid glycoprotein (AGP), a human glycoprotein displaying complex type N-glycans. Binding of rgp160/rgp120 to agarose-coupled AGP was dose-dependent, saturable, calcium-, pH- and temperature-dependent. Binding was inhibited by soluble AGP, asialo-AGP, fetuin, beta-D-GlcNAc47-BSA, alpha-D-Man20-BSA, mannan, complex-type asialo-agalacto-tetraanternary precursor oligosaccharide from human AGP and oligomannose 9 from porcine thyroglobulin; fully deglycosylated AGP was not inhibitory. The three AGP glycoforms separated on immobilized ConA bound rgp160 to the same extent as did unfractionated AGP. These findings extend our previous results on the carbohydrate-binding properties of HIV-1 envelope (Env) glycoprotein in that they demonstrate the involvement of AGP glycan moieties in the binding to rgp160/rgp120. Preincubation of rgp160 with AGP or mannan significantly reduced its binding to monocyte-derived macrophages (MDM), suggesting that AGP may play a role in preventing binding of soluble or virus-bound Env glycoprotein to CD4+ monocytic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795416     DOI: 10.1007/bf00731863

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  33 in total

1.  Microheterogeneity of the inner core region of yeast manno-protein.

Authors:  T Nakajima; C E Ballou
Journal:  Biochem Biophys Res Commun       Date:  1975-09-16       Impact factor: 3.575

2.  LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur.

Authors:  S Wain-Hobson; J P Vartanian; M Henry; N Chenciner; R Cheynier; S Delassus; L P Martins; M Sala; M T Nugeyre; D Guétard
Journal:  Science       Date:  1991-05-17       Impact factor: 47.728

Review 3.  Drug binding to human alpha-1-acid glycoprotein in health and disease.

Authors:  J M Kremer; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1988-03       Impact factor: 25.468

4.  The asparagine-linked oligosaccharides on bovine fetuin. Structural analysis of N-glycanase-released oligosaccharides by 500-megahertz 1H NMR spectroscopy.

Authors:  E D Green; G Adelt; J U Baenziger; S Wilson; H Van Halbeek
Journal:  J Biol Chem       Date:  1988-12-05       Impact factor: 5.157

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Structures of asparagine-linked oligosaccharides of the glycoprotein fetuin having sialic acid linked to N-acetylglucosamine.

Authors:  D A Cumming; C G Hellerqvist; M Harris-Brandts; S W Michnick; J P Carver; B Bendiak
Journal:  Biochemistry       Date:  1989-07-25       Impact factor: 3.162

7.  Fractionation of glycopeptides by affinity column chromatography on concanavalin A-sepharose.

Authors:  S Ogata; T Muramatsu; A Kobata
Journal:  J Biochem       Date:  1975-10       Impact factor: 3.387

8.  Changes in the blood level and affinity to concanavalin A of rat plasma glycoproteins during acute inflammation and hepatoma growth.

Authors:  A Koj; A Dubin; H Kasperczyk; J Bereta; A H Gordon
Journal:  Biochem J       Date:  1982-09-15       Impact factor: 3.857

9.  Carbohydrate binding properties of the envelope glycoproteins of human immunodeficiency virus type 1.

Authors:  M Haidar; N Seddiki; J C Gluckman; L Gattegno
Journal:  Glycoconj J       Date:  1992-12       Impact factor: 2.916

10.  Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis.

Authors:  E Fenouillet; B Clerget-Raslain; J C Gluckman; D Guétard; L Montagnier; E Bahraoui
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  7 in total

1.  Human alpha1-acid glycoprotein binds to CCR5 expressed on the plasma membrane of human primary macrophages.

Authors:  A Atemezem; E Mbemba; R Vassy; H Slimani; L Saffar; L Gattegno
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

2.  Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry.

Authors:  Adriana Bora; Ceereena Ubaida Mohien; Raghothama Chaerkady; Linda Chang; Richard Moxley; Ned Sacktor; Norman Haughey; Justin C McArthur; Robert Cotter; Avindra Nath; David R Graham
Journal:  J Neurovirol       Date:  2014-07-24       Impact factor: 2.643

3.  Flow cytometric detection of alpha-1-acid glycoprotein on feline circulating leucocytes.

Authors:  S Paltrinieri; I Marchini; M E Gelain
Journal:  Aust Vet J       Date:  2012-06-05       Impact factor: 1.281

4.  Tissue distribution of a feline AGP related protein (fAGPrP) in cats with feline infectious peritonitis (FIP).

Authors:  S Paltrinieri; A Giordano; F Ceciliani; G Sironi
Journal:  J Feline Med Surg       Date:  2004-04       Impact factor: 2.015

Review 5.  The feline acute phase reaction.

Authors:  Saverio Paltrinieri
Journal:  Vet J       Date:  2007-08-07       Impact factor: 2.688

6.  Serum alpha1-acid glycoprotein (AGP) concentration in non-symptomatic cats with feline coronavirus (FCoV) infection.

Authors:  Saverio Paltrinieri; Cecilia Metzger; Mara Battilani; Vanessa Pocacqua; Maria Elena Gelain; Alessia Giordano
Journal:  J Feline Med Surg       Date:  2007-03-06       Impact factor: 2.015

7.  Association between faecal shedding of feline coronavirus and serum alpha1-acid glycoprotein sialylation.

Authors:  Saverio Paltrinieri; Maria E Gelain; Fabrizio Ceciliani; Alba M Ribera; Mara Battilani
Journal:  J Feline Med Surg       Date:  2008-08-12       Impact factor: 2.015

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.